IPO registrations (S-1, F-1) · Registrants
Cellectar Biosciences, Inc.
- SEC CIK
- 1279704 · filings on EDGAR ↗
- Former names
- NOVELOS THERAPEUTICS, INC. (2005–2014); COMMON HORIZONS INC (2004–2005)
- Registration
- Form S-1, first filed 2008-06-03, last 2026-05-29; 20 initial registrations, 23 amendments
- Outcome
- Final prospectus filed 2010-07-22; declared effective 2008-06-23; withdrawal requested 2016-10-21
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 100 CAMPUS DRIVE, Florham Park, NJ 07932
- EIN
- 04-3321804
- Ticker
- CLRB (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Cellectar Biosciences, Inc. on the corporate pages
On this site
- Form 5500 plan sponsor: CELLECTAR BIOSCIENCES, INC EXACT (EIN (EXACT))
- Form D issuer: Cellectar Biosciences, Inc. EXACT (CIK (EXACT))
- SEC filer: Cellectar Biosciences, Inc. EXACT (CIK (EXACT))
Filings 89
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2008-06-03 | S-1 | S-1 (registration) | NOVELOS THERAPEUTICS, INC. | 0001144204-08-033468 ↗ |
| 2008-06-23 | EFFECT | EFFECT (declared effective) | NOVELOS THERAPEUTICS, INC. | 9999999995-08-001990 ↗ |
| 2008-09-30 | EFFECT | EFFECT (declared effective) | NOVELOS THERAPEUTICS, INC. | 9999999995-08-002998 ↗ |
| 2009-04-27 | EFFECT | EFFECT (declared effective) | NOVELOS THERAPEUTICS, INC. | 9999999995-09-001055 ↗ |
| 2009-09-15 | S-1 | S-1 (registration) | NOVELOS THERAPEUTICS, INC. | 0001144204-09-048519 ↗ |
| 2009-12-07 | S-1/A | S-1/A (amendment) | NOVELOS THERAPEUTICS, INC. | 0001144204-09-063456 ↗ |
| 2010-01-26 | S-1/A | S-1/A (amendment) | NOVELOS THERAPEUTICS, INC. | 0001144204-10-003656 ↗ |
| 2010-02-05 | S-1/A | S-1/A (amendment) | NOVELOS THERAPEUTICS, INC. | 0001144204-10-005744 ↗ |
| 2010-02-12 | EFFECT | EFFECT (declared effective) | NOVELOS THERAPEUTICS, INC. | 9999999995-10-000498 ↗ |
| 2010-05-03 | EFFECT | EFFECT (declared effective) | NOVELOS THERAPEUTICS, INC. | 9999999995-10-001339 ↗ |
| 2010-05-11 | S-1 | S-1 (registration) | NOVELOS THERAPEUTICS, INC. | 0001144204-10-026204 ↗ |
| 2010-06-25 | S-1/A | S-1/A (amendment) | NOVELOS THERAPEUTICS, INC. | 0001144204-10-034982 ↗ |
| 2010-07-07 | S-1/A | S-1/A (amendment) | NOVELOS THERAPEUTICS, INC. | 0001144204-10-036844 ↗ |
| 2010-07-08 | EFFECT | EFFECT (declared effective) | NOVELOS THERAPEUTICS, INC. | 9999999995-10-002077 ↗ |
| 2010-07-22 | 424B1 | 424B1 (final prospectus) | NOVELOS THERAPEUTICS, INC. | 0001144204-10-038917 ↗ |
| 2011-02-07 | EFFECT | EFFECT (declared effective) | NOVELOS THERAPEUTICS, INC. | 9999999995-11-000363 ↗ |
| 2011-07-01 | S-1 | S-1 (registration) | NOVELOS THERAPEUTICS, INC. | 0001144204-11-038631 ↗ |
| 2011-08-15 | S-1/A | S-1/A (amendment) | NOVELOS THERAPEUTICS, INC. | 0001144204-11-047364 ↗ |
| 2011-09-14 | S-1/A | S-1/A (amendment) | NOVELOS THERAPEUTICS, INC. | 0001144204-11-052959 ↗ |
| 2011-11-09 | S-1/A | S-1/A (amendment) | NOVELOS THERAPEUTICS, INC. | 0001144204-11-062631 ↗ |
| 2011-11-23 | S-1/A | S-1/A (amendment) | NOVELOS THERAPEUTICS, INC. | 0001144204-11-066593 ↗ |
| 2011-11-30 | EFFECT | EFFECT (declared effective) | NOVELOS THERAPEUTICS, INC. | 9999999995-11-003416 ↗ |
| 2011-12-02 | 424B1 | 424B1 (final prospectus) | NOVELOS THERAPEUTICS, INC. | 0001144204-11-068179 ↗ |
| 2012-04-09 | S-1 | S-1 (registration) | NOVELOS THERAPEUTICS, INC. | 0001144204-12-020785 ↗ |
| 2012-05-14 | S-1/A | S-1/A (amendment) | NOVELOS THERAPEUTICS, INC. | 0001144204-12-028689 ↗ |
| 2012-06-06 | S-1/A | S-1/A (amendment) | NOVELOS THERAPEUTICS, INC. | 0001144204-12-033494 ↗ |
| 2012-06-07 | EFFECT | EFFECT (declared effective) | NOVELOS THERAPEUTICS, INC. | 9999999995-12-001755 ↗ |
| 2012-06-08 | 424B1 | 424B1 (final prospectus) | NOVELOS THERAPEUTICS, INC. | 0001144204-12-034010 ↗ |
| 2012-07-17 | S-1 | S-1 (registration) | NOVELOS THERAPEUTICS, INC. | 0001144204-12-039891 ↗ |
| 2012-07-26 | EFFECT | EFFECT (declared effective) | NOVELOS THERAPEUTICS, INC. | 9999999995-12-002289 ↗ |
| 2012-11-20 | S-1 | S-1 (registration) | NOVELOS THERAPEUTICS, INC. | 0001144204-12-064070 ↗ |
| 2013-01-31 | S-1/A | S-1/A (amendment) | NOVELOS THERAPEUTICS, INC. | 0001144204-13-005014 ↗ |
| 2013-02-04 | EFFECT | EFFECT (declared effective) | NOVELOS THERAPEUTICS, INC. | 9999999995-13-000380 ↗ |
| 2013-02-15 | 424B1 | 424B1 (final prospectus) | NOVELOS THERAPEUTICS, INC. | 0001144204-13-009475 ↗ |
| 2013-05-09 | EFFECT | EFFECT (declared effective) | NOVELOS THERAPEUTICS, INC. | 9999999995-13-001455 ↗ |
| 2013-05-09 | EFFECT | EFFECT (declared effective) | NOVELOS THERAPEUTICS, INC. | 9999999995-13-001459 ↗ |
| 2014-05-19 | S-1 | S-1 (registration) | Cellectar Biosciences, Inc. | 0001144204-14-032183 ↗ |
| 2014-07-07 | S-1/A | S-1/A (amendment) | Cellectar Biosciences, Inc. | 0001144204-14-041708 ↗ |
| 2014-08-06 | S-1/A | S-1/A (amendment) | Cellectar Biosciences, Inc. | 0001144204-14-047322 ↗ |
| 2014-08-14 | EFFECT | EFFECT (declared effective) | Cellectar Biosciences, Inc. | 9999999995-14-002508 ↗ |
| 2014-08-18 | 424B4 | 424B4 (final prospectus) | Cellectar Biosciences, Inc. | 0001144204-14-050899 ↗ |
| 2015-09-03 | EFFECT | EFFECT (declared effective) | Cellectar Biosciences, Inc. | 9999999995-15-002438 ↗ |
| 2015-12-18 | S-1 | S-1 (registration) | Cellectar Biosciences, Inc. | 0001144204-15-071768 ↗ |
| 2015-12-18 | EFFECT | EFFECT (declared effective) | Cellectar Biosciences, Inc. | 9999999995-15-003325 ↗ |
| 2016-03-21 | S-1/A | S-1/A (amendment) | Cellectar Biosciences, Inc. | 0001144204-16-089210 ↗ |
| 2016-04-14 | S-1/A | S-1/A (amendment) | Cellectar Biosciences, Inc. | 0001144204-16-094228 ↗ |
| 2016-04-14 | EFFECT | EFFECT (declared effective) | Cellectar Biosciences, Inc. | 9999999995-16-004214 ↗ |
| 2016-04-18 | 424B4 | 424B4 (final prospectus) | Cellectar Biosciences, Inc. | 0001144204-16-094876 ↗ |
| 2016-07-27 | EFFECT | EFFECT (declared effective) | Cellectar Biosciences, Inc. | 9999999995-16-005251 ↗ |
| 2016-10-21 | RW | RW (withdrawal request) | Cellectar Biosciences, Inc. | 0001144204-16-128964 ↗ |
| 2016-10-21 | S-1 | S-1 (registration) | Cellectar Biosciences, Inc. | 0001144204-16-128994 ↗ |
| 2016-10-28 | S-1 | S-1 (registration) | Cellectar Biosciences, Inc. | 0001144204-16-130269 ↗ |
| 2016-11-09 | S-1/A | S-1/A (amendment) | Cellectar Biosciences, Inc. | 0001144204-16-132783 ↗ |
| 2016-11-14 | S-1/A | S-1/A (amendment) | Cellectar Biosciences, Inc. | 0001144204-16-133493 ↗ |
| 2016-11-18 | S-1/A | S-1/A (amendment) | Cellectar Biosciences, Inc. | 0001144204-16-135417 ↗ |
| 2016-11-22 | EFFECT | EFFECT (declared effective) | Cellectar Biosciences, Inc. | 9999999995-16-006300 ↗ |
| 2016-11-22 | EFFECT | EFFECT (declared effective) | Cellectar Biosciences, Inc. | 9999999995-16-006302 ↗ |
| 2016-11-23 | 424B4 | 424B4 (final prospectus) | Cellectar Biosciences, Inc. | 0001144204-16-136426 ↗ |
| 2017-09-20 | EFFECT | EFFECT (declared effective) | Cellectar Biosciences, Inc. | 9999999995-17-002407 ↗ |
| 2017-11-09 | S-1 | S-1 (registration) | Cellectar Biosciences, Inc. | 0001144204-17-057760 ↗ |
| 2017-11-22 | EFFECT | EFFECT (declared effective) | Cellectar Biosciences, Inc. | 9999999995-17-003053 ↗ |
| 2018-06-15 | S-1 | S-1 (registration) | Cellectar Biosciences, Inc. | 0001144204-18-034439 ↗ |
| 2018-07-18 | S-1/A | S-1/A (amendment) | Cellectar Biosciences, Inc. | 0001144204-18-038716 ↗ |
| 2018-07-26 | S-1MEF | S-1MEF (added securities) | Cellectar Biosciences, Inc. | 0001144204-18-040249 ↗ |
| 2018-07-26 | EFFECT | EFFECT (declared effective) | Cellectar Biosciences, Inc. | 9999999995-18-001899 ↗ |
| 2018-07-27 | 424B4 | 424B4 (final prospectus) | Cellectar Biosciences, Inc. | 0001144204-18-040478 ↗ |
| 2019-05-31 | S-1 | S-1 (registration) | Cellectar Biosciences, Inc. | 0001144204-19-029289 ↗ |
| 2019-06-11 | EFFECT | EFFECT (declared effective) | Cellectar Biosciences, Inc. | 9999999995-19-001329 ↗ |
| 2020-05-08 | S-1 | S-1 (registration) | Cellectar Biosciences, Inc. | 0001104659-20-058896 ↗ |
| 2020-05-20 | S-1/A | S-1/A (amendment) | Cellectar Biosciences, Inc. | 0001104659-20-063931 ↗ |
| 2020-06-02 | S-1MEF | S-1MEF (added securities) | Cellectar Biosciences, Inc. | 0001104659-20-069148 ↗ |
| 2020-06-02 | EFFECT | EFFECT (declared effective) | Cellectar Biosciences, Inc. | 9999999995-20-001312 ↗ |
| 2020-06-04 | 424B4 | 424B4 (final prospectus) | Cellectar Biosciences, Inc. | 0001104659-20-069526 ↗ |
| 2020-08-20 | EFFECT | EFFECT (declared effective) | Cellectar Biosciences, Inc. | 9999999995-20-002217 ↗ |
| 2021-02-01 | EFFECT | EFFECT (declared effective) | Cellectar Biosciences, Inc. | 9999999995-21-000375 ↗ |
| 2022-11-23 | S-1 | S-1 (registration) | Cellectar Biosciences, Inc. | 0001104659-22-121762 ↗ |
| 2022-12-02 | EFFECT | EFFECT (declared effective) | Cellectar Biosciences, Inc. | 9999999995-22-003450 ↗ |
| 2023-10-30 | EFFECT | EFFECT (declared effective) | Cellectar Biosciences, Inc. | 9999999995-23-003132 ↗ |
| 2024-07-23 | EFFECT | EFFECT (declared effective) | Cellectar Biosciences, Inc. | 9999999995-24-002242 ↗ |
| 2025-01-29 | S-1 | S-1 (registration) | Cellectar Biosciences, Inc. | 0001410578-25-000060 ↗ |
| 2025-02-06 | EFFECT | EFFECT (declared effective) | Cellectar Biosciences, Inc. | 9999999995-25-000342 ↗ |
| 2025-06-26 | S-1 | S-1 (registration) | Cellectar Biosciences, Inc. | 0001104659-25-062834 ↗ |
| 2025-06-30 | S-1/A | S-1/A (amendment) | Cellectar Biosciences, Inc. | 0001104659-25-063849 ↗ |
| 2025-07-01 | EFFECT | EFFECT (declared effective) | Cellectar Biosciences, Inc. | 9999999995-25-002137 ↗ |
| 2025-07-02 | 424B4 | 424B4 (final prospectus) | Cellectar Biosciences, Inc. | 0001104659-25-064897 ↗ |
| 2025-10-20 | S-1 | S-1 (registration) | Cellectar Biosciences, Inc. | 0001104659-25-100854 ↗ |
| 2026-05-19 | S-1 | S-1 (registration) | Cellectar Biosciences, Inc. | 0001104659-26-063918 ↗ |
| 2026-05-29 | S-1/A | S-1/A (amendment) | Cellectar Biosciences, Inc. | 0001104659-26-067933 ↗ |
| 2026-06-01 | EFFECT | EFFECT (declared effective) | Cellectar Biosciences, Inc. | 9999999995-26-001826 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| BERNS PAUL L | Director | 4 | 2014–2016 | ||
| Genn John Patrick | Officer | VP of Business Development | 3 | 2014–2015 | |
| HILL STEPHEN A | Director | 12 | 2014–2020 | ||
| Kolean Chad J | Officer | CFO; Chief Financial Officer; VP, CFO and Treasurer; VP, Chief Financial Officer | 12 | 2014–2026 | |
| McNeil Kathryn M | Officer | See Remarks | 1 | 2014 | |
| NEIS JOHN | Director | 22 | 2014–2026 | ||
| Pedder Simon | Director,Officer | President and CEO | 2 | 2014 | |
| Weichert Jamey P | Director,Officer; Officer | Chief Scientific Officer | 2 | 2014–2016 | |
| Chen Bihua | Director,TenPercentOwner | 1 | 2014 | ||
| Cormorant Asset Management, LLC | TenPercentOwner | 1 | 2014 | ||
| Cormorant Global Healthcare GP, LLC | TenPercentOwner | 1 | 2014 | ||
| Cormorant Global Healthcare Master Fund, LP | TenPercentOwner | 1 | 2014 | ||
| MARXE AUSTIN W & GREENHOUSE DAVID M | TenPercentOwner | 4 | 2014–2015 | ||
| Szakacs Cameron | Officer | VP of Clinical Development | 2 | 2014 | |
| AWM Investment Company, Inc. | TenPercentOwner | 19 | 2015–2016 | ||
| CARUSO JAMES V | Director,Officer | Chief Executive Officer; President and CEO; President & CEO | 24 | 2015–2026 | |
| Loren Stefan | Director; Other | 13 | 2015–2026 | ||
| WISCONSIN ALUMNI RESEARCH FOUNDATION | TenPercentOwner | 1 | 2016 | ||
| Hertzberg Richard | Other; TenPercentOwner | 3 | 2016 | ||
| Longcor Jarrod | Officer | Chief Business Officer; Chief Operating Officer; Sr. VP of Corp Dev & Ops | 23 | 2016–2026 | |
| DRISCOLL FREDERICK W | Director | 12 | 2017–2026 | ||
| Friend John E. II | Officer | Chief Medical Officer; VP, Chief Medical Officer | 6 | 2017–2021 | |
| Swirsky Douglas J | Director | 12 | 2017–2026 | ||
| Hamill John P. | Officer | Interim CFO | 1 | 2017 | |
| POSNER BRIAN M | Officer | Chief Financial Officer | 4 | 2018–2019 | |
| Bernhardt Charles Thomas III | Officer | Interim CFO | 1 | 2019 | |
| Elefant Dov | Officer | Chief Financial Officer | 8 | 2019–2022 | |
| Grachev Igor D | Officer | Chief Medical Officer | 2 | 2020 | |
| Chanan-Khan Asher | Director | 7 | 2021–2026 | ||
| Lea Darrell Shane | Officer | Chief Commercial Officer | 4 | 2022–2024 | |
| Shustov Andrei | Officer | Senior Vice President, Medical | 4 | 2023–2024 | |
| Gu Andrew | Director | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2023-09-22 | Cellectar Biosciences, Inc. | Biotechnology | $24,500,000 | $24,500,000 | 21 | 1 |
| 2021-01-08 | Cellectar Biosciences, Inc. | Pharmaceuticals | $20,499,993 | $20,499,993 | 16 | 1 |
| 2019-05-31 | Cellectar Biosciences, Inc. | Pharmaceuticals | $14,645,000 | $5,045,000 | 11 | 1 |
| 2017-10-13 | Cellectar Biosciences, Inc. | Pharmaceuticals | $7,766,164 | $7,766,164 | 3 | 1 |
| 2014-08-15 | Cellectar Biosciences, Inc. | Pharmaceuticals | $1,000,000 | $617,500 | 8 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.